Form 8-K
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): October 28, 2009
AMICUS THERAPEUTICS,
INC.
(Exact name of registrant as
specified in its charter)
|
|
|
|
|
Delaware |
|
001-33497 |
|
71-0869350 |
(State or other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
6 Cedar Brook Drive,
Cranbury, NJ
|
|
08512 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number,
including area code: (609) 662-2000
|
|
(Former name or former address if changed since last report.) |
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers.
(d) On October 28, 2009, Margaret G. McGlynn, R.Ph. was elected to the Board of Directors of
Amicus Therapeutics, Inc. (the Company). Ms. McGlynn will join the Board of Directors as an
independent director. Ms. McGlynn has not yet been appointed to any
Board committees.
There is no arrangement or understanding between Ms. McGlynn and any other person pursuant
to which Ms. McGlynn was elected as director of the Company. There are no relationships or
transactions in which Ms. McGlynn has or will have an interest, or was or is a party, requiring
disclosure under Item 404(a) of Regulation S-K.
A copy of the press release announcing Ms. McGlynns election is furnished as Exhibit 99.1
to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits .
99.1 Press Release, dated November 3, 2009
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
|
AMICUS THERAPEUTICS, INC.
|
|
Date: November 3, 2009 |
By: |
/s/ GEOFFREY P. GILMORE
|
|
|
|
Name: |
Geoffrey P. Gilmore |
|
|
|
Title: |
Senior Vice President and General Counsel |
|
3
EXHIBIT INDEX
|
|
|
|
|
Exhibit No. |
|
Description |
|
99.1 |
|
|
Press Release, dated November 3, 2009 |
Exhibit 99.1
Exhibit
99.1
FOR IMMEDIATE RELEASE
Amicus Therapeutics Appoints Margaret G. McGlynn, R.Ph.,
to Board of Directors
Cranbury, NJ, November 3, 2009 Amicus Therapeutics (Nasdaq: FOLD) today announced the
appointment of Margaret G. McGlynn, R.Ph., to its Board of Directors. Ms. McGlynn most recently
served as President of Vaccines and Infectious Diseases for Merck & Co., Inc.
John F. Crowley, President and CEO of Amicus Therapeutics stated, Margies vast industry expertise
and insight will be invaluable to Amicus as we execute on our key strategic priorities and continue
our focus on building shareholder value with our innovative technologies. We are very pleased to
welcome her to our Board.
About Margaret G. McGlynn, R.Ph.
Margaret McGlynn recently retired from Merck and Co., Inc. after more than 26 years of service.
Her most recent role was President of Merck Vaccines and Infectious Diseases from 2005 through
November 2009. McGlynn joined Merck in 1983 and served in a variety of marketing, sales and
managed care roles. In addition to her position at Merck, McGlynn serves as a member of the Board
of Directors for Air Products and Chemicals. She is also a member of the National Industrial
Advisory Committee at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences and
recently served as a member of the Global Alliance for Vaccine Immunization (GAVI) Board and
Executive Committee. McGlynn holds a B.S. in Pharmacy and a MBA in Marketing from the State
University of New York at Buffalo.
About Amicus Therapeutics
Amicus Therapeutics is a late-stage biopharmaceutical company developing novel, oral therapeutics
known as pharmacological chaperones for the treatment of a range of human genetic diseases. Amicus
is initially targeting lysosomal storage disorders and diseases of neurodegeneration with unmet
medical needs.
CONTACTS:
Jenene Thomas
Director, Investor Relations
(609) 662-5084
FOLD G